B
APGE icon

Braidwell’s Apogee Therapeutics APGE Stock Holding History

Braidwell’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.3M Sell
478,667
-96,400
-17% -$7M 1.34% 29
2025
Q4 		$43.4M Sell
575,067
-863,678
-60% -$54.4M 1.39% 29
2025
Q3 		$57.2M Sell
1,438,745
-39,767
-3% -$1.52M 1.7% 20
2025
Q2 		$64.2M Sell
1,478,512
-61,850
-4% -$2.35M 2.2% 18
2025
Q1 		$57.5M Hold
1,540,362
– – 2.02% 20
2024
Q4 		$69.8M Sell
1,540,362
-102,864
-6% -$5.25M 2.07% 15
2024
Q3 		$96.5M Sell
1,643,226
-748,816
-31% -$35.9M 2.74% 9
2024
Q2 		$94.1M Buy
2,392,042
+549,527
+30% +$26.7M 2.95% 8
2024
Q1 		$122M Buy
1,842,515
+1,161,414
+171% +$50.7M 3.95% 5
2023
Q4 		$19M Buy
681,101
+189,988
+39% +$3.81M 0.7% 42
2023
Q3 		$10.5M Buy
+491,113
New +$10.8M 0.33% 75

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Braidwell's APGE Position: Q1 2026 in Review

Braidwell reduced its Apogee Therapeutics (APGE) stake by 17% in Q1 2026, selling an estimated $7M and leaving 478,667 shares worth $40.3M. The position accounts for 1.34% of the portfolio, ranked #29.

Braidwell first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $122M in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Braidwell held 478,667 shares of Apogee Therapeutics worth $40.3M as of Q1 2026.
  • Braidwell sold 96,400 Apogee Therapeutics shares in Q1 2026, an estimated $7M.
  • Apogee Therapeutics made up 1.34% of Braidwell's portfolio in Q1 2026, its #29 holding.
  • Braidwell first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Braidwell's Apogee Therapeutics position peaked at $122M in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.